Popular Articles

Cephalon Provides Clinical Update On Lestaurtinib In Relapsed Acute Myelogenous Leukemia
Cephalon, Inc. (Nasdaq: CEPH) announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.

Agreements Secured For Pre-Pandemic Vaccine For The UK
Agreements have been signed between the UK Government and vaccine manufacturers to secure supplies of up to 90 million doses of pre-pandemic H1N1 vaccine before a pandemic begins, the Department of Health announced today.
News of the day
Appeals Court Panel Says Pharmacists Must Distribute Emergency Contraception Under Washington State Regulation
A three-judge panel of the U.S. Circuit Court of Appeals for the 9th Circuit on Wednesday unanimously ruled to lift an injunction blocking Washington state officials from penalizing pharmacists who refused to dispense the emergency contraception pill Plan B, the Los Angeles Times reports (Williams, Los Angeles Times, 7/9). The panel said the district court judge who issued the injunction refused to consider women"s need for EC (Egelko, San Francisco Chronicle, 7/9). The panel"s ruling is part of a larger case before the district court involving the constitutionality of a 2007 state regulation requiring pharmacies to stock and dispense EC. Joyce Roper, an assistant attorney general for Washington state, said the appeals court ruling means that the 2007 regulation will take immediate effect.The plaintiffs in the case, Stromans -- a supermarket pharmacy owner -- and two pharmacists employed elsewhere, argued that the state regulation requiring pharmacists to stock and dispense EC violated their First Amendment right to freedom of religion (Los Angeles Times, 7/9). The regulation said that pharmacies must stock and fill legally prescribed prescriptions but allowed individual pharmacists to object on moral or religious grounds if another pharmacist was available, in person or by telephone, to fill the order (San Francisco Chronicle, 7/9). The plaintiffs argued that the regulation would force them to choose between following their religious beliefs and keeping their jobs. They contended that EC prevents implantation of a fertilized egg, which they equated with abortion. The U.S. District Court in Seattle awarded the plaintiffs the temporary injunction in November 2007, pending trial on the constitutionality of the regulation (Los Angeles Times, 7/9). Plan B contains a high dose of a drug found in most birth control pills that generally prevents ovulation or the fertilization of an egg. Recent research suggests that it does not prevent a fertilized egg from implanting in the uterus (Woodward, AP/Seattle Post-Intelligencer, 7/8). FDA in April lowered the age limit for nonprescription purchase of Plan B from 18 to 17 (San Francisco Chronicle, 7/9). Appeals Panel Returns Case to District CourtThe appeals court panel ruled that the freedom to exercise one"s religion "does not relieve an individual of the obligation to comply with a valid and neutral law of general applicability." The panel added, "Any refusal to dispense -- regardless of whether it is motivated by religion, morals, conscience, ethics, discriminatory prejudices or personal distaste for a patient -- violates the rules" (Los Angeles Times, 7/9). The panel ordered the district judge to reconsider the 2007 regulation under Supreme Court standards that allow states to pass neutral laws that may affect religious practices. According to the panel, the regulation does not aim to interfere with religious practices or beliefs and is intended to promote patients" health. In addition, the panel said the district court judge did not consider how the injunction would affect "sexually active women of childbearing age who will be denied reasonable access to Plan B" (San Francisco Chronicle, 7/9). According to the Times, the panel"s ruling could foretell future judgments in the case, including that a patient"s right to timely medication surpasses a pharmacist"s personal beliefs (Los Angeles Times, 7/9).
Public Health

Discovery Of Breast Cancer Gene That's Blocked By Blood Pressure Drug

Researchers have identified a gene that is overexpressed in up to 20 percent of breast cancers and that could be blocked in the lab by a currently available blood pressure drug, according to a new study from the University of Michigan Comprehensive Cancer Center. The gene, called AGTR1, caused normal breast cells to behave like cancer cells. This behavior was reversed by treatment with the blood pressure drug losartan. Tumors in mice that expressed AGTR1 shrunk by 30 percent eight weeks after treatment with losartan, a drug approved by the U.S. Food and Drug Administration to treat high blood pressure. "We suspect our analysis has uncovered a new crop of potentially important breast cancer genes. What"s also exciting is this gene is blocked by a drug that"s already available on the market," says study author Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Endowed Professor of Pathology at the U-M Medical School. Results of the study appear online the week of June 1 in the Proceedings of the National Academy of Sciences. The researchers looked at gene expression profiling data from nearly 3,200 microarrays available in the Oncomine database, a tool that allows rapid comparison of thousands of genes in human cancers. The researchers found genes that were dramatically overexpressed within subsets of tumors. The gene that came up most often was ERBB2, which is better known as HER2, a gene that is overexpressed in 25 percent to 30 percent of all human breast cancers. HER2 is blocked by the targeted therapy Herceptin. The next most commonly seen gene behind ERBB2 was AGTR1, which was seen in 10 percent to 20 percent of breast tumors. Specifically, AGTR1 was overexpressed only in tumors that were ERBB2-negative and that expressed the estrogen receptor, known as ER-positive. AGTR1 was found to be as much as 100-fold overexpressed in some tumors. "AGTR1 is very analogous to HER2 or ERBB2. HER2 is a bona fide treatment target for patients with that type of breast cancer. This research defines a novel subtype of ER-positive breast cancer that we hope can be similarly targeted for treatment," says Chinnaiyan, a Howard Hughes Medical Institute investigator. The researchers tested in cell cultures and in mice the effect of losartan on AGTR1-positive tumors. When losartan was introduced, the AGTR1-positive tumors were reduced, while AGTR1-negative tumors were not affected. In the mice studies, losartan shrank AGTR1-positive tumors by 20 percent after two weeks and by 30 percent after eight weeks. "Losartan may be a viable therapy for women with AGTR1 over-expressing breast tumors. This study lays the groundwork for a clinical trial to test losartan to treat breast cancers positive for AGTR1," Chinnaiyan says. Researchers are discussing a possible clinical trial, but one is not currently designed or recruiting for participants. Breast cancer statistics: 194,280 Americans will be diagnosed with breast cancer this year and 40,610 will die from the disease, according to the American Cancer Society Additional authors: Daniel R. Rhodes, Bushra Ateeq, Qi Cao, Scott A. Tomlins, Rohit Mehra, Bharathi Laxman, Shanker Kalyana-Sundaram, Robert J. Lonigro, Beth E. Helgeson, Mahaveer S. Bhojani, Alnawaz Rehemtulla, Celina G. Kleer, Daniel F. Hayes, Peter C. Lucas and Sooryanarayana Varambally Funding: Department of Defense Era of Hope Scholar Award, Early Detection Research Network Biomarker Devleopmental Lab, Department of Defense, U-M Cancer Center Bioinformatics Core, Rackham Predoctoral Fellowship, Clinical Translational Research Award from the Burroughs Welcome Foundation and Doris Duke Charitable Foundation Distinguished Clinical Scientist Award. Losartan was provided by Merck U.S.A. Disclosure: The University of Michigan has filed a patent on AGTR1 and is currently seeking a commercial partner to help bring this technology to market. Nicole Fawcett University of Michigan Health System


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):